Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision [Seeking Alpha]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Seeking Alpha
RYTM's upcoming March 20th FDA PDUFA decision for setmelanotide in acquired hypothalamic obesity could expand the addressable market to 25,000–28,000 patients globally. Positive Phase 3 TRANSCEND data showed a -16.4% mean BMI reduction for setmelanotide, supporting its potential as the first targeted therapy for acquired hypothalamic obesity. RYTM trades at a high valuation (20.1x forward EV/sales), reflecting investor expectations for regulatory success and significant future revenue expansion. geckophotos/iStock via Getty Images Thesis Rhythm Pharmaceuticals ( RYTM reported a 4Q25 GAAP EPS of -$0.73, a figure which beat estimates by about $0.07. Revenue came in at $57.3 million, up almost 37% year-over-year and $1.09 million above expectations. For FY26, the expectations are for Non-GAAP operating expenses to fall in the range This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned,
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Rhythm Pharmaceuticals (RYTM) had its price target lowered by HC Wainwright from $110.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals (RYTM) had its price target lowered by Citigroup Inc. from $136.00 to $131.00. They now have a "buy" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals (RYTM) had its price target lowered by Royal Bank Of Canada from $140.00 to $130.00. They now have an "outperform" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals (RYTM) had its price target lowered by Citizens Jmp from $176.00 to $152.00. They now have a "market outperform" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals (RYTM) had its price target lowered by Bank of America Corporation from $145.00 to $139.00. They now have a "buy" rating on the stock.MarketBeat
RYTM
Earnings
- 2/26/26 - Beat
RYTM
Sec Filings
- 3/16/26 - Form 8-K
- 3/16/26 - Form 4
- 3/6/26 - Form 4
- RYTM's page on the SEC website